Robert Goodman
Beyond AirAbout Robert Goodman
Robert Goodman joined Beyond Air’s (XAIR) Board in June 2025 and was determined by the Board to be independent under Nasdaq rules at appointment; he later transitioned to serve as Interim Chief Commercial Officer in November 2025. He is a retired U.S. Army officer with 30+ years of commercial leadership spanning BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, Pfizer, and WEP Clinical; he holds an undergraduate degree from Norwich University. Appointment effective June 13, 2025 (press release) with Board action recorded June 16, 2025 (8‑K); independence affirmed at appointment; interim CCO role announced November 10, 2025, which generally implies loss of director independence while serving as an executive .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| WEP Clinical | Chief Commercial Officer | 2023–2024 | Helped accelerate and increase total contract values and revenue growth by over 30% YoY |
| BioTelemetry | Division President | Through 2021 | Led $2.1B sell-side transaction to Royal Philips in 2021 |
| Cardiocore | SVP, Sales & Marketing | 2008–2017 | Company later acquired by BioTelemetry |
| Thermo Fisher Scientific | Senior Director, Head of Sales & Marketing | 2007–2008 | Executive commercial leadership |
| Philips Healthcare | Executive leadership | Not disclosed | Senior leadership post-BioTelemetry acquisition |
| Pfizer | Executive leadership | Not disclosed | Named among prior leadership roles |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Fourth Frontier | Director | Not disclosed | Contributed to 510(k) FDA device approval and supported successful Series B financing |
Board Governance
- Appointment and status: Appointed effective June 13, 2025; Board action on June 16, 2025; determined independent at appointment .
- Committees: As of appointment, Board had not assigned Goodman to any board committees (Audit, Compensation, Nominating) .
- Engagement: Company encourages annual meeting attendance; two directors attended 2024 annual meeting (pre‑Goodman) .
- Executive role transition: Appointed Interim Chief Commercial Officer on November 10, 2025, indicating he was serving as an executive while on the Board .
Fixed Compensation
| Component | Goodman Specific | XAIR Non-Employee Director Structure (Historical) |
|---|---|---|
| Cash retainer | Not disclosed; Board stated “typical compensation” for non-employee directors | $0 cash fees reported for FY2024 for non-employee directors |
| Meeting/committee fees | Not disclosed | Not disclosed; tables show no cash fees |
| Equity – Options (grant date fair value) | Not disclosed | FY2024 option awards: $51,300 for Forbes, Bentsur, Lucera, Lee; $102,600 for Carey |
| Equity – RSUs | Not disclosed | None shown for non-employee directors in FY2024 |
| Change-in-control terms | Not disclosed for Goodman | Director agreements include automatic vesting of unvested options/RSUs upon change of control |
Performance Compensation
| Metric | Director Compensation Applicability | Notes |
|---|---|---|
| Non-equity incentive plan comp | None disclosed for non-employee directors in FY2024 | XAIR director tables report dashes (no non-equity incentives) |
| Performance metrics (TSR, revenue, EBITDA, ESG) | Not disclosed for Goodman | No performance-tied metrics disclosed for directors in proxies |
Other Directorships & Interlocks
| Company | Public/Private | Role | Potential Interlock Risk |
|---|---|---|---|
| Fourth Frontier | Not disclosed | Director | Health tech exposure; no specific XAIR transaction disclosed |
| Philips Healthcare | Public (Royal Philips) | Executive leadership (prior) | Strategic/commercial experience; no related-party dealings with XAIR disclosed |
| BioTelemetry/Cardiocore/Thermo Fisher/Pfizer | Public/private | Executive roles (prior) | Sector network depth; Company reported no related‑party transactions involving Goodman |
Expertise & Qualifications
- Education and military: Undergraduate degree from Norwich University; retired U.S. Army officer .
- Commercial leadership: Led $2.1B sale of BioTelemetry to Philips; delivered >30% YoY revenue growth at WEP Clinical; extensive sales and marketing leadership across medtech/pharma .
- Health tech governance: Board role at Fourth Frontier contributing to 510(k) and financing outcomes .
Equity Ownership
| Item | Amount/Status |
|---|---|
| Common shares beneficially owned | 40,000 (Direct) |
| Ownership % of shares outstanding | ~0.046% (40,000 / 86,369,869 outstanding as of 4/23/2025) |
| Vested vs unvested breakdown | Not disclosed |
| Derivative securities (options/warrants) | None reported on Form 3 at appointment |
| Shares pledged as collateral | Not disclosed |
Insider Filings
| Filing Date | Form | Event Date | Title of Security | Shares | Ownership Form | Notes |
|---|---|---|---|---|---|---|
| 2025-07-09 | Form 3 | 2025-06-16 | Common Stock | 40,000 | Direct | Initial statement of beneficial ownership upon joining Board |
Governance Assessment
- Independence risk: Goodman’s appointment as Interim Chief Commercial Officer in November 2025 is a governance red flag for board independence, as executive service typically disqualifies “independent” status under exchange rules while in role; close monitoring of committee participation and independence disclosures is warranted .
- Committees/attendance: Committee assignment for Goodman was not determined at appointment; no attendance data for Goodman disclosed yet, limiting evaluation of committee effectiveness and engagement .
- Compensation alignment: XAIR historically compensates non‑employee directors with equity options and no cash fees, supporting alignment; Goodman’s specific grants have not been disclosed, so current pay-for-performance alignment for him cannot be assessed .
- Related‑party/transactions: Company disclosed no Item 404(a) related‑party transactions involving Goodman at appointment, reducing immediate conflict risk .
- Ownership signal: Initial stake of 40,000 shares is positive but modest; future filings (Form 4) should be tracked for incremental ownership or equity awards post‑appointment and following interim executive role .
RED FLAGS
- Director independence compromised by concurrent Interim CCO role starting November 2025; ensure separation of duties and recusal from compensation decisions affecting his executive role .
- Lack of disclosed committee assignments and director-specific compensation details post-appointment limits transparency into governance influence and incentives .
Notes
- Company committees as of 2024/2025: Audit (Lucera chair; members Bentsur, Carey), Compensation (Lee chair; members Lucera, Bentsur), Nominating (Lucera chair; members Lee, Forbes); Goodman was not on the Board at those disclosures .